Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767995 | 1.00 | KDM4E (0.56) | KDM4ESMN1; SMN2NPC1RAB9ANR2F2 | |
| SCHEMBL377867 | 0.84 | ALDH1A1 (0.48) | KDM4ESMN1; SMN2NPC1RAB9ANR2F2 | |
| SCHEMBL2767694 | 0.84 | LMNA (0.47) | KDM4ESMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL377526 | 0.84 | ALDH1A1 (0.48) | KDM4ESMN1; SMN2NPC1RAB9ANR2F2 | |
| SCHEMBL2767692 | 0.84 | LMNA (0.47) | KDM4ESMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL2768306 | 0.83 | KDM4E (0.53) | KDM4ESMN1; SMN2NPC1RAB9ANR2F2 | |
| SCHEMBL28653669 | 0.83 | MGLL (0.51) | — | |
| SCHEMBL28653667 | 0.83 | MGLL (0.51) | — | |
| SCHEMBL28927825 | 0.83 | MGLL (0.51) | — | |
| SCHEMBL14645770 | 0.83 | MGLL (0.56) | ALDH1A1ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7700599-B2 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | KDM4E 4252/4885SMN1; SMN2 2072/4885NPC1 711/4885 |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GPR68, GPR88, GPR3 | KDM4E 2013/4885SMN1; SMN2 3150/4885NPC1 2662/4885 |
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | KDM4E 4443/4885SMN1; SMN2 1860/4885NPC1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.